2010乳腺癌（英文）.pptVIP

* * * * * SOLTI-0701: PFS ITT population *One - sided PFS Probability Months 1.00 0.75 0.50 0.25 0.0 1.5 3.0 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0 0.00 SOR+CAP PL+CAP *One - sided PFS Probability Months 1.00 0.75 0.50 0.25 0.0 1.5 3.0 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0 0.00 SOR+CAP PL+CAP SOR + CAP n=115 PL + CAP n=114 Median PFS, mos 6.4 4.1 HR (95% CI) 0.576 (0.410–0.809) p= .0006* 42% reduction in the risk of disease progression Baselga et al. ECCO-ESMO 2009; Abstract 3LBA PARP inhibition Hudis. SABCS 2009; Plenary presentation 72% pCR (18/25) rate In the neo-adjuvant setting 73% ORR (1